Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Predicted CAGR for the Hepatitis D Market Over the Forecast Period of 2025 to 2034?
In recent times, the hepatitis D market has consistently witnessed growth. The size of this market is poised to grow from $0.72 billion in 2024 to $0.76 billion in 2025, marking a compound annual growth rate (CAGR) of 4.6%. Factors driving this growth include inadequate treatment alternatives, high occurrence in areas with regular outbreaks, co-infection with hepatitis B, inadequate awareness and diagnosis rates, as well as government vaccination drives.
In the coming years, the hepatitis D market size is predicted to experience consistent growth, with an estimated worth of $0.90 billion in 2029 and a compound annual growth rate (CAGR) of 4.4%. This predicted growth is driven by factors such as the broadening of reimbursement policies for new therapies, increased healthcare sector investments, greater use of combination treatments, an amplified hepatitis B vaccination coverage, and the escalation of public health initiatives. Key trends for the forecast period consist of improvements in molecular diagnostic tools, a shift towards personalized medicine in managing liver disease, the creation of cutting-edge RNA-based therapies, the broadening of clinical trials for hepatitis D treatments, and the incorporation of telemedicine in managing hepatitis.
Which Primary Drivers Are Supporting the Continued Expansion of the Hepatitis D Market?
The growth of the hepatitis D market is predicted to be fuelled by the escalating incidence of hepatitis B. Hepatitis B is a viral disease impacting the liver, leading to effects such as yellowing of skin or eyes, exhaustion, and stomach discomfort, and can result in chronic liver conditions or liver cancer if not administered promptly. The augmented Hepatitis B cases can be traced back to things like unshielded sexual interaction, needle exchanges, transmission from mother to child at birth, and inadequate vaccination in certain zones. Hepatitis D hinges on the Hepatitis B virus for its multiplication as it exploits the Hepatitis B’s surface antigen to infect the liver cells, rendering the co-contamination of both pathogens a crucial driver in the escalation of liver conditions. For exemplification, as per the US Department of Health and Human Services in November 2023, there was an 11% hike in the newly detected chronic Hepatitis B cases in 2022 compared to 2021. Consequently, the escalating incidence of hepatitis B is stimulating the development of the hepatitis D market.
Get Your Free Sample of the Global Hepatitis D Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp
Who are the key firms paving the way for growth in the Hepatitis D market?
Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, Biorex Diagnostics Ltd.
What Key Trends Are Currently Impacting the Hepatitis D Market’s Development?
The hepatitis D market is witnessing significant advancements as major players in the field are concentrating on the development of innovative formulations like recombinant vaccines. These vaccines are designed to increase the efficiency of immunization and offer durable protection against the virus. These vaccines are produced by integrating a gene that encodes a viral protein into a host organism such as bacteria or yeast. This protein is then used to stimulate an immune response without causing the disease. As an illustration, VBI Vaccines Inc., a biotechnology company based in the U.S., got approval from Health Canada in December 2022 for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)]. This vaccine is for active immunization against all recognized subtypes of hepatitis B in adults who are 18 years or older. This approval also covers the prevention of hepatitis D, which is caused by the delta agent and cannot occur without a hepatitis B infection. The approval was granted based on the encouraging results from two critical Phase 3 clinical trials, protect and constant. These studies showed higher seroprotection rates with PreHevbrio as compared to the single-antigen engerix-B vaccine.
Get Instant Access to the Global Hepatitis D Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report
Which Segments Play a Crucial Role in the Expansion of the Hepatitis D Market?
The hepatitis d market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis
3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online Pharmacies
4) By End-Users: Clinic, Hospital, Other End Users
Subsegments:
1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D
2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D
Which Geographical Regions Are Pioneering Growth in the Hepatitis D Market?
North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Do Experts Define the Scope of the Hepatitis D Market?
Hepatitis D, also known as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is considered the most severe form of viral hepatitis and occurs only in individuals who are already infected with the hepatitis B virus (HBV). Hepatitis D virus depends on hepatitis B virus for its replication and survival, making it a co-infection or superinfection.
Browse Through More Similar Reports By The Business Research Company:
Hemophilia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report
Acquired Hemophilia Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report
Insulin Pens, Syringes, Pumps And Injectors Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: